Glycosylated SV2A and SV2B Mediate the Entry of Botulinum Neurotoxin E into Neurons

被引:185
|
作者
Dong, Min [1 ,2 ]
Liu, Huisheng [1 ,2 ]
Tepp, William H. [3 ]
Johnson, Eric A. [3 ]
Janz, Roger [4 ,5 ]
Chapman, Edwin R. [1 ,2 ]
机构
[1] Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA
[2] Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA
[3] Univ Wisconsin, Dept Food Microbiol & Toxicol, Madison, WI 53706 USA
[4] Univ Texas Houston, Sch Med, WM Keck Ctr Learning & Memory, Houston, TX 77030 USA
[5] Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1091/mbc.E08-07-0765
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Botulinum neurotoxin E (BoNT/E) can cause paralysis in humans and animals by blocking neurotransmitter release from presynaptic nerve terminals. How this toxin targets and enters neurons is not known. Here we identified two isoforms of the synaptic vesicle protein SV2, SV2A and SV2B, as the protein receptors for BoNT/E. BoNT/E failed to enter neurons cultured from SV2A/B knockout mice; entry was restored by expressing SV2A or SV2B, but not SV2C. Mice lacking SV2B displayed reduced sensitivity to BoNT/E. The fourth luminal domain of SV2A or SV2B alone, expressed in chimeric receptors by replacing the extracellular domain of the low-density lipoprotein receptor, can restore the binding and entry of BoNT/E into neurons lacking SV2A/B. Furthermore, we found disruption of a N-glycosylation site (N573Q) within the fourth luminal domain of SV2A rendered the mutant unable to mediate the entry of BoNT/E and also reduced the entry of BoNT/A. Finally, we demonstrate that BoNT/E failed to bind and enter ganglioside-deficient neurons; entry was rescued by loading exogenous gangliosides into neuronal membranes. Together, the data reported here demonstrate that glycosylated SV2A and SV2B act in conjunction with gangliosides to mediate the entry of BoNT/E into neurons.
引用
收藏
页码:5226 / 5237
页数:12
相关论文
共 50 条
  • [41] N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A
    Yao, Guorui
    Zhang, Sicai
    Mahrhold, Stefan
    Lam, Kwok-ho
    Stern, Daniel
    Bagramyan, Karine
    Perry, Kay
    Kalkum, Markus
    Rummel, Andreas
    Dong, Min
    Jin, Rongsheng
    NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2016, 23 (07) : 656 - 662
  • [42] N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A
    Guorui Yao
    Sicai Zhang
    Stefan Mahrhold
    Kwok-ho Lam
    Daniel Stern
    Karine Bagramyan
    Kay Perry
    Markus Kalkum
    Andreas Rummel
    Min Dong
    Rongsheng Jin
    Nature Structural & Molecular Biology, 2016, 23 : 656 - 662
  • [43] Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model
    Trenite, D. G. A. Kasteleijn-Nolst
    Genton, P.
    Parain, D.
    Masnou, P.
    Steinhoff, B. J.
    Jacobs, T.
    Pigeolet, E.
    Stockis, A.
    Hirsch, E.
    NEUROLOGY, 2007, 69 (10) : 1027 - 1034
  • [44] Dysfunction of SV2A elicites dopaminergic hyperactivity via interacting accumbal gabaergic neurons in rats
    Ohno, Y.
    Tokudome, K.
    Ikari, A.
    Iguchi, Y.
    Sugahara, T.
    Kunisawa, N.
    Kato, M.
    Serikawa, T.
    Shimizu, S.
    JOURNAL OF NEUROCHEMISTRY, 2019, 150 : 100 - 100
  • [45] SV2A protein: role in the anticonvulsant mechanism of action of levetiracetam
    Rafal M. Kaminski
    Pharmacological Reports, 2010, 62 : 435 - 436
  • [46] SV2A protein: role in the anticonvulsant mechanism of action of levetiracetam
    Kaminski, Rafal M.
    PHARMACOLOGICAL REPORTS, 2010, 62 (02) : 435 - 436
  • [47] EVIDENCE FOR A DIFFERENTIAL INTERACTION OF BRIVARACETAM AND LEVETIRACETAM WITH THE SV2A PROTEIN
    Wood, M.
    Urbain, D.
    Gillard, M.
    EPILEPSIA, 2015, 56 : 215 - 215
  • [48] Levetiracetam Reverses Synaptic Deficits Produced by Overexpression of SV2A
    Nowack, Amy
    Malarkey, Erik B.
    Yao, Jia
    Bleckert, Adam
    Hill, Jessica
    Bajjalieh, Sandra M.
    PLOS ONE, 2011, 6 (12):
  • [49] Visualization of SV2A conformations in situ by the use of Protein Tomography
    Lynch, Berkley A.
    Matagne, Alain
    Braennstrom, Annika
    von Euler, Anne
    Jansson, Magnus
    Hauzenberger, Elenor
    Soederhaell, J. Arvid
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 375 (04) : 491 - 495
  • [50] Targeting hippocampal amyloidogenesis with SV2A protein modulator levetiracetam
    Kasatkina, Ludmila A.
    Gumenyuk, Vitaliy P.
    Lisakovska, Olha O.
    Trikash, Irene O.
    BIOCHEMICAL PHARMACOLOGY, 2022, 197